| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Majlen A Dilweg, Tamara A M Mocking, Pantelis Maragkoudakis, Gerard J P van Westen, Laura H Heitman, Adriaan P IJzerman, Willem Jespers, Daan van der E. Stereochemical optimization of RSC medicinal chemistry. 2024-09-30. PMID:39345718. |
inhibition of net-mediated reuptake of norepinephrine by monoamine reuptake inhibitors has been the main therapeutic strategy to treat disorders such as depression, adhd and parkinson's disease. |
2024-09-30 |
2024-10-02 |
Not clear |
| Guilherme Fusetto Veronesi, Alessandra Gabellone, Anneka Tomlinson, Marco Solmi, Christoph U Correll, Samuele Cortes. Treatments in the pipeline for attention-deficit/hyperactivity disorder (ADHD) in adults. Neuroscience and biobehavioral reviews. 2024-06-24. PMID:38914177. |
while several pharmacological and non-pharmacological interventions had evidence of superiority compared to the control condition from a single rct, centanafadine (norepinephrine, dopamine, and serotonin re-uptake inhibitor) was the only treatment with evidence of efficacy on adhd core symptoms (small effect size=0.28-0.40) replicated in at least one additional rct, alongside reasonable tolerability. |
2024-06-24 |
2024-06-27 |
Not clear |
| Geeta Ilipilla, L Eugene Arnol. The role of adrenergic neurotransmitter reuptake inhibitors in the ADHD armamentarium. Expert opinion on pharmacotherapy. 2024-06-20. PMID:38900676. |
due to their effects on norepinephrine, dopamine, and serotonin neurotransmission, they benefit both adhd and comorbid disorders and have some other advantages including longer duration of action and fewer adverse effects compared to stimulants. |
2024-06-20 |
2024-06-23 |
Not clear |
| Fumika Sato, Akihito Suzuki, Keisuke Noto, Toshinori Shirata, Muneaki Kanno, Ryota Kobayashi, Koichi Otan. Serotonin syndrome induced by overdose of atomoxetine alone in a patient with attention-deficit hyperactivity disorder: A case report. PCN reports : psychiatry and clinical neurosciences. vol 1. issue 3. 2024-06-13. PMID:38868692. |
atomoxetine is a norepinephrine reuptake inhibitor used for the treatment of attention-deficit hyperactivity disorder (adhd). |
2024-06-13 |
2024-06-15 |
Not clear |
| Kamilla W Miskowiak, Zacharias K Obel, Riccardo Gugliemo, Caterina Del Mar Bonnin, Christopher R Bowie, Vicente Balanzá-Martínez, Katherine E Burdick, Andre F Carvalho, Annemieke Dols, Katie Douglas, Peter Gallagher, Lars V Kessing, Beny Lafer, Kathryn E Lewandowski, Carlos López-Jaramillo, Anabel Martinez-Aran, Roger S McIntyre, Richard J Porter, Scot E Purdon, Ayal Schaffer, Paul R A Stokes, Tomiki Sumiyoshi, Ivan J Torres, Tamsyn E Van Rheenen, Lakshmi N Yatham, Allan H Young, Eduard Vieta, Gregor Hasle. Efficacy and safety of established and off-label ADHD drug therapies for cognitive impairment or attention-deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force. Bipolar disorders. 2024-03-04. PMID:38433530. |
abnormalities in dopamine and norepinephrine signaling are implicated in cognitive impairments in bipolar disorder (bd) and attention-deficit hyperactivity disorder (adhd). |
2024-03-04 |
2024-03-06 |
Not clear |
| X Zhang, M S Berridge, S M Apana, W Slikker, M G Paule, John Talpo. Discontinuation of methylphenidate after long-term exposure in nonhuman primates. Neurotoxicology and teratology. 2023-03-09. PMID:36893929. |
the blockage of the dopamine transporter (dat) and the norepinephrine transporter (net) by mph may help with adhd symptoms by boosting monoamine levels in the synapse. |
2023-03-09 |
2023-08-14 |
human |
| Damian Koevoet, P K H Deschamps, J L Keneman. Catecholaminergic and cholinergic neuromodulation in autism spectrum disorder: A comparison to attention-deficit hyperactivity disorder. Frontiers in neuroscience. vol 16. 2023-01-23. PMID:36685234. |
deficiencies in catecholaminergic systems [dopamine (da), norepinephrine (ne)] in adhd are obvious targets for stimulant treatment. |
2023-01-23 |
2023-08-14 |
Not clear |
| Maeri Yamamoto, Toshiya Inad. Positron emission tomography studies in adult patients with attention-deficit/hyperactivity disorder. Japanese journal of radiology. 2022-12-08. PMID:36480104. |
we found that, although, disturbances of dopamine, serotonin, and norepinephrine functions have been implicated in adhd, no characteristic findings have been identified from pet studies in patients with adhd. |
2022-12-08 |
2023-08-14 |
Not clear |
| b' Jind\\xc5\\x99ich Mourek, Jaroslav Pokorn\\xc3\\xb. ADHD - What Is the Meaning of Sex-dependent Incidence Differences? Prague medical report. vol 123. issue 4. 2022-11-23. PMID:36416460.' |
the picture of adhd includes various cognitive dysfunctions with one possible cause in norepinephrine and dopamine insufficiency. |
2022-11-23 |
2023-08-14 |
Not clear |
| Sonia Carreón-Trujillo, Daniela Vázquez-González, Juan Carlos Coron. Atomoxetine Decreases Mitochondrial Biogenesis, Fission and Fusion In Human Neuron-like Cells But Does Not Alter Antioxidant Defences. Cell biochemistry and biophysics. 2022-11-08. PMID:36346546. |
atomoxetine (atx) is a presynaptic norepinephrine transporter (net) inhibitor widely prescribed for attention-deficit/hyperactivity disorder (adhd) due to its low abuse potential and absence of psychostimulant effects. |
2022-11-08 |
2023-08-14 |
human |
| Maria Ptukha, Zoia Fesenko, Anastasia Belskaya, Arina Gromova, Arseniy Pelevin, Natalia Kurzina, Raul R Gainetdinov, Anna Volnov. Effects of Atomoxetine on Motor and Cognitive Behaviors and Brain Electrophysiological Activity of Dopamine Transporter Knockout Rats. Biomolecules. vol 12. issue 10. 2022-10-27. PMID:36291693. |
atomoxetine (atx) is a selective norepinephrine transporter (net) inhibitor that is currently used for adhd treatment. |
2022-10-27 |
2023-08-14 |
rat |
| Anna Kabanova, Elena Cavani, Nikos K Logothetis, Oxana Eschenk. Feasibility of Canine Adenovirus Type 2 (CAV2) Based Vector for the Locus Coeruleus Optogenetic Activation in Non-Transgenic Rats: Implications for Functional Studies. Brain sciences. vol 12. issue 7. 2022-07-27. PMID:35884711. |
the locus coeruleus norepinephrine (lc-ne) system modulates many visceral and cognitive functions, while lc-ne dysfunction leads to neurological and neurodegenerative conditions such as sleep disorders, depression, adhd, or alzheimer's disease. |
2022-07-27 |
2023-08-14 |
rat |
| b' Jue Huang, Nicole Mauche, Michael Rullmann, Christine Ulke, Georg-Alexander Becker, Marianne Patt, Franziska Zientek, Swen Hesse, Osama Sabri, Maria Strau\\xc3\\x9. Association between Individual Norepinephrine Transporter (NET) Availability and Response to Pharmacological Therapy in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Brain sciences. vol 12. issue 8. 2022-07-27. PMID:35892406.' |
association between individual norepinephrine transporter (net) availability and response to pharmacological therapy in adults with attention-deficit/hyperactivity disorder (adhd). |
2022-07-27 |
2023-08-14 |
Not clear |
| b' Jue Huang, Nicole Mauche, Michael Rullmann, Christine Ulke, Georg-Alexander Becker, Marianne Patt, Franziska Zientek, Swen Hesse, Osama Sabri, Maria Strau\\xc3\\x9. Association between Individual Norepinephrine Transporter (NET) Availability and Response to Pharmacological Therapy in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Brain sciences. vol 12. issue 8. 2022-07-27. PMID:35892406.' |
the role of the norepinephrine transporter (net) has received increased focus in recent studies on the pathogenesis of attention-deficit/hyperactivity disorder (adhd). |
2022-07-27 |
2023-08-14 |
Not clear |
| Keith Mather, Michelle Condre. Extended-Release Viloxazine for Children and Adolescents With Attention Deficit Hyperactivity Disorder. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. vol 27. issue 5. 2022-07-18. PMID:35845566. |
non-stimulant medication therapy for children, adolescents, and young adults with attention-deficit/hyperactivity disorder (adhd) has included alpha 2-agonists (guanfacine and clonidine) as well as a norepinephrine reuptake inhibitor (atomoxetine) for multiple years. |
2022-07-18 |
2023-08-14 |
Not clear |
| Lenard A Adler, Julie Adams, Jessica Madera-McDonough, Eva Kohegyi, Mary Hobart, Denise Chang, Mark Angelicola, Robert McQuade, Michael Liebowit. Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials. Journal of clinical psychopharmacology. 2022-06-02. PMID:35652746. |
centanafadine is an inhibitor of norepinephrine, dopamine, and serotonin reuptake transporters under investigation for the treatment of attention-deficit/hyperactivity disorder (adhd). |
2022-06-02 |
2023-08-14 |
Not clear |
| Nikhil M Urs, Sharonda Harris, Sara M Green, Mayank M Kuma. A Role for Cortical Dopamine in the Paradoxical Calming Effects of Psychostimulants. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. vol 36 Suppl 1. 2022-05-13. PMID:35554609. |
together, these data suggest that elevation of pfc dopamine and not norepinephrine or serotonin as a convergent mechanism for the paradoxical psychostimulant effects observed in adhd therapy. |
2022-05-13 |
2023-08-13 |
mouse |
| Pınar Bingöl-Kızıltunç, Esra Yürümez, Huban Atill. Does methylphenidate treatment affect functional and structural ocular parameters in patients with attention deficit hyperactivity disorder? - A prospective, one year follow-up study. Indian journal of ophthalmology. vol 70. issue 5. 2022-05-03. PMID:35502047. |
methylphenidate hydrochloride, which blocks the reuptake mechanisms of dopamine and norepinephrine, is used in attention deficit hyperactivity disorder (adhd) treatment. |
2022-05-03 |
2023-08-13 |
Not clear |
| Natalia Kurzina, Anastasia Belskaya, Arina Gromova, Alla Ignashchenkova, Raul R Gainetdinov, Anna Volnov. Modulation of Spatial Memory Deficit and Hyperactivity in Dopamine Transporter Knockout Rats Frontiers in psychiatry. vol 13. 2022-04-11. PMID:35401264. |
adhd also is known to be associated with impairment of multiple aspects of cognition, including spatial memory, however, it remains unclear how modulation of the norepinephrine system can affect these deficits. |
2022-04-11 |
2023-08-13 |
rat |
| Katrin Ruppert, Christoph Geffert, Hans-Willi Clement, Christian Bachmann, Michael Haberhausen, Eberhard Schulz, Christian Fleischhaker, Monica Biscaldi-Schäfe. Therapeutic drug monitoring of atomoxetine in children and adolescents with attention-deficit/ hyperactivity disorder: a naturalistic study. Journal of neural transmission (Vienna, Austria : 1996). 2022-04-08. PMID:35391568. |
the selective norepinephrine reuptake inhibitor atomoxetine is potentially among the first-line pharmacotherapy options for adhd. |
2022-04-08 |
2023-08-13 |
Not clear |